Medicare Will Cover GLP-1 Weight Loss Drugs at $50/Month Starting July 2026

After years of lobbying, policy debates, and growing public demand, Medicare will begin covering GLP-1 weight loss medications starting July 1, 2026. The new CMS Balance Model pilot program will bring drugs like Wegovy and Zepbound within reach for millions of Medicare beneficiaries at an estimated copay of roughly $50 per month. If you or a family member is on Medicare and has been paying out of pocket for GLP-1 therapy, or has been unable to afford it at all, this is the most significant policy shift in weight loss treatment in decades.

What Is the CMS Balance Model?

The CMS Balance Model is a voluntary pilot program launched by the Centers for Medicare and Medicaid Services. It allows participating Medicare Part D plans to cover FDA-approved anti-obesity medications, specifically GLP-1 receptor agonists, as a covered pharmacy benefit. Until now, Medicare has explicitly excluded weight loss drugs from Part D coverage, even when those same medications were covered for diabetes under different brand names.

Under the Balance Model, CMS will share a portion of the drug cost with participating Part D plans, making it financially viable for insurers to add these medications to their formularies. The program launches on July 1, 2026 and will run for an initial three-year period. CMS expects the program to reduce long-term healthcare spending by lowering rates of obesity-related conditions like heart disease, type 2 diabetes, and joint replacements. For a detailed breakdown of how the program works, see this Medicare GLP-1 coverage guide.

Which Medications Are Covered?

The Balance Model covers FDA-approved GLP-1 medications indicated for chronic weight management. At launch, the two primary drugs expected to be on participating plan formularies are:

• Wegovy (semaglutide 2.4 mg weekly injection) by Novo Nordisk
• Zepbound (tirzepatide weekly injection) by Eli Lilly

Some plans may also cover oral options. If you want to understand how semaglutide works across its different formulations, this complete Ozempic guide covers the science behind the medication in detail.

Who Qualifies for Coverage?

To be eligible for GLP-1 coverage under the CMS Balance Model, you must meet all of the following criteria:

• Enrolled in a participating Medicare Part D plan. Not all Part D plans will join the pilot program. You will need to verify that your specific plan has opted in.
• BMI of 30 or higher (clinical obesity), OR a BMI of 27 or higher with at least one weight-related comorbidity such as type 2 diabetes, hypertension, high cholesterol, obstructive sleep apnea, or cardiovascular disease.
• A prescription from a licensed healthcare provider who documents your BMI and qualifying conditions.

Your doctor will need to submit documentation to your Part D plan confirming you meet these criteria. Plans may also require prior authorization, so it is important to start the process early.

What Will It Cost?

The exact copay will depend on your specific Part D plan and its formulary tier placement. However, CMS estimates that most beneficiaries will pay approximately $50 per month out of pocket for their GLP-1 medication under the Balance Model. This is a dramatic reduction from the current self-pay prices, which range from $500 to $1,349 per month depending on the medication. For many Medicare beneficiaries living on fixed incomes, this copay structure makes GLP-1 therapy genuinely accessible for the first time.

How to Prepare Right Now

July 1 is less than three months away. If you want to be ready to start GLP-1 therapy as soon as coverage begins, take these steps now:

• Talk to your doctor. Schedule an appointment to discuss whether a GLP-1 medication is appropriate for you. Your provider will need to document your BMI and any qualifying comorbidities.
• Verify your Part D plan participates. Call your insurance company or check the CMS website after May 2026 for a list of participating plans. If your plan is not participating, you may be able to switch during the next open enrollment period.
• Get your labs done. Many plans will require recent bloodwork, including A1C, lipid panel, and metabolic panel, as part of the prior authorization process.
• Ask about prior authorization timelines. Some plans may take two to four weeks to process a prior authorization. Starting early means you will not be waiting weeks after the program launches.

What If You Are Under 65?

The CMS Balance Model applies specifically to Medicare beneficiaries. If you are under 65 and do not have Medicare, this program will not apply to you directly. However, the competitive pressure from Medicare coverage is already driving prices down across the entire GLP-1 market. Online telehealth programs now offer compounded and branded GLP-1 medications at significantly lower prices than even a year ago, with monthly costs starting as low as $149 for some programs.

If you are not on Medicare but want to explore GLP-1 weight loss options, you can find the best GLP-1 program for you by comparing providers based on pricing, medication options, and medical oversight. Many telehealth platforms offer month-to-month plans with no long-term commitment, making it easier to try GLP-1 therapy without the high upfront costs that defined this market just a year ago.

The Bottom Line

Medicare GLP-1 coverage starting July 2026 is a watershed moment for weight loss treatment in America. For the first time, millions of older adults will have affordable access to medications that clinical trials have shown produce 15-22% body weight reduction. If you are on Medicare and meet the eligibility criteria, start preparing now so you can begin treatment as soon as the program launches. And if you are under 65, keep an eye on the market because the ripple effects of this policy change are making GLP-1 therapy more affordable for everyone.